Loading data
SANGNasdaq
| Unit: USD | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 200.07 m USD | 236.69 m USD | 247.28 m USD | 252.53 m USD | 224.35 m USD |
| Cost of revenue | 56.4 m USD | 74.94 m USD | 74.46 m USD | 79.74 m USD | 67.46 m USD |
| Gross profit | 140.66 m USD | 161.75 m USD | 172.82 m USD | 172.79 m USD | 156.89 m USD |
| Research and development expense | 42.9 m USD | 42.15 m USD | 39.54 m USD | 37.47 m USD | 34.16 m USD |
| Interest expense | 2.02 m USD | 4.01 m USD | 6.64 m USD | 6.77 m USD | 3.86 m USD |
| Profit before tax | -86.55 m USD | -6.34 m USD | -9.5 m USD | -31.96 m USD | -104.39 m USD |
| Income tax expense | -5.46 m USD | -1.33 m USD | -840 k USD | -2.93 m USD | 6.39 m USD |
| Net income (reported basis) | -81.09 m USD | -5.01 m USD | -8.66 m USD | -29.03 m USD | -110.78 m USD |
| Basic earnings per share | -2.44 USD/share | -0.15 USD/share | -0.26 USD/share | -0.88 USD/share | -3.52 USD/share |
| Diluted earnings per share | -2.44 USD/share | -0.15 USD/share | -0.26 USD/share | -0.88 USD/share | -3.52 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.